

### Medical Research

### **Future Fund**

#### MRFF RAO Webinar

28 August 2023

Assoc. Prof. Ruth Griffiths, Director – Patients and Infrastructure Ms Shelley Li, Director – Mission Strategy and Implementation Dr Ragini Singh, Director – Grants Management Office Assoc. Prof. Cindy Thamrin, Director – Performance and Evaluation



#### Contents

- **1.** Acknowledgement of Country
- 2. Webinar overview
- **3.** Open Funding calls
- **4.** MRFF Reporting activities
- 5. Post-award and key messages
- 6. Q&A
- 7. Keep Connected



#### MRFF Research Administration Officer Webinars

Aim to:

- provide practical information to the sector and Research Administration Officers (RAOs) in particular about MRFF administrative arrangements
- assist RAOs and potential grantees in better supporting MRFF funded research and researchers
- aid the implementation of any changes to MRFF grant administration
- seek feedback from RAOs, with a view toward continuous improvement of MRFF grant administration



### MRFF Open/Upcoming Funding Calls

Assoc. Prof. Ruth Griffiths, Director – Patients and Infrastructure


Ms Shelley Li, Director – Mission Strategy and Implementation

- MRFF 2023 Post-Acute Sequelae of COVID-19
- MRFF 2023 Childhood Mental Health
- MRFF 2023 Primary Health
- MRFF 2023 Targeted Translation Research Accelerator



#### MRFF Post-Acute Sequelae of COVID-19 (PASC) Research Plan

- \$50 million over 5 years from 2023-24 to improve outcomes for people experiencing PASC
  - Funding through the Emerging Priorities and Consumer Driven Research Initiative
- Terms of Reference available at <u>https://www.health.gov.au/resources/publicatio</u> <u>ns/post-acute-sequelae-of-covid-19-pasc-</u> <u>research-plan-expert-advisory-panel-terms-of-</u> <u>reference</u>



Medical Research Future Fund



### Purpose of the PASC Expert Advisory Panel

- The EAP will provide the Minister for Health and Aged Care advice on research investments required to meet the following objectives:
  - generate evidence on the current and future impacts of PASC in the specific Australian context (including individual health and wellbeing, carers, communities, health system)
  - design and evaluate clinical pathways and models of care, co-led by general practitioners and primary care, for Australians with PASC, including to address inequities in access and outcomes
  - generate new diagnostic and therapeutic approaches to prevent the occurrence of PASC and/or improve health outcomes for individuals with PASC



#### Purpose of the PASC Research Plan EAP cont'd

- Additionally, the EAP is also to consider how to:
  - Consider priority populations, including but not limited to people living in rural, regional and remote communities, First Nations, and Culturally and Linguistically Diverse people



### MRFF Childhood Mental Health Research Plan

- \$50 million over 4 years from 2024-25 to support research to improve patient care, translate new discoveries into clinical practice and encourage researchers to work together with consumers.
  - Funding through the Emerging Priorities and Consumer Driven Research Initiative
- Terms of Reference available at <u>https://www.health.gov.au/resources/publica</u> <u>tions/childhood-mental-health-research-plan-</u> <u>expert-advisory-panel-terms-of-reference</u>



### Purpose of the Childhood Mental Health Research Planet Expert Advisory Panel

- The EAP will provide the Minister for Health and Aged Care advice on research investments required to meet the following objectives:
  - generate knowledge on the determinants and protective factors for optimal mental health and wellbeing in children
  - generate knowledge to improve access to, and delivery of, evidence-based treatments and to reduce mental illness and psychological distress in children
  - address inequities in childhood mental health and psychological distress outcomes
  - inform implementation of current and future policies and programs in child mental health.

#### Purpose of the Childhood Mental Health Research Plan EAP Future Fund cont'd

- Additionally, the EAP is also to consider how to:
  - consider priority populations, including but not limited to people living in rural, regional and remote communities, First Nations, and Culturally and Linguistically Diverse people.

Medical Research



### 2023 Primary Health Research Plan

- \$50 million over 4 years from 2024-25 to drive innovation in primary care
  - Funding through the Emerging Priorities and Consumer Driven Research Initiative, and Primary Health Care Initiative
- Terms of Reference available at <u>https://www.health.gov.au/resources/publica</u> <u>tions/primary-health-research-plan-expert-</u> <u>advisory-panel-terms-of-reference</u>





### Purpose of the Primary Care Research Plan Expert Advisory Panel

- The EAP will provide the Minister for Health and Aged Care advice on research investments required to meet the following objectives:
  - identify and evaluate multidisciplinary models of primary care (e.g. those relating to voluntary patient registration, innovative models in rural and remote communities, team-based care), to deliver higher quality and more effective care with a focus on addressing inequities in access and outcomes experienced by priority populations
  - enhance linkage and/or use of research data infrastructure sources (e.g. electronic medical record repositories and administrative datasets) to identify and evaluate models of primary care excellence and/or support health system planning
  - support translational research carried out with practitioners in primary care settings, and knowledge transfer among practitioners in primary care and academia to improve person-centred care.



#### Purpose of the Primary Care Research Plan EAP cont'd

- Additionally, the EAP is also to consider how to:
  - involve all stakeholders relevant to the research and its translation in its conceptualisation, design and implementation, including health care consumers and providers
  - best support research translation and implementation in primary care to raise the profile of primary care as a field of choice for health practitioners and academics.



# 2023 Targeted Translation Research Accelerator Research Plan

- \$77.5 million from 2023-24 to support research into diabetes and cardiovascular disease
  - Research will be into both Type 1 and Type 2 diabetes
  - Funding provided through the Preventive and Public Health Research Initiative
- Terms of Reference available at: <u>https://www.health.gov.au/resources/pub</u> <u>lications/targeted-translation-research-</u> <u>accelerator-plan-expert-advisory-panel-</u> <u>terms-of-reference</u>





#### Purpose of the Targeted Translation Research Accelerator Expert Advisory Panel

- The EAP will provide the Minister for Health and Aged Care advice on research investments required to meet the following objectives:
  - accelerate promising therapeutic approaches and devices for the prevention, early detection, management and treatment of disease related complications for diabetes (Type 1 and Type 2) and cardiovascular disease
  - support implementation of effective novel interventions and models of care for patients experiencing multi-morbidity across diabetes (Type 1 and Type 2), cardiovascular disease and their risk factors
  - address inequities in treatment, management, access to care and health outcomes for those experiencing diabetes (Type 1 and Type 2) and cardiovascular disease
  - inform implementation of current and future policies and programs in diabetes (Type 1 and Type 2) and cardiovascular disease.



### Managing MRFF grants

Dr Ragini Singh

**Director - Grants Management** Office

- Progress and final reports
- Grants management developments





### Progress and final reports for MRFF grants

Progress and final reports are essential for ensuring achievement of MRFF grant opportunity objectives and outcomes.

- Tips
  - If something is not going to plan, keep Health apprised through the reporting process or contact the grant administration hub to advise of urgent issues occurring outside the reporting cycle.
  - If you're unable to submit a progress report by the due date, get in touch with the grant administration hub to let them know or consider whether a variation request might be necessary.
  - In addition to risks and mitigation strategies, highlight your wins and newsworthy findings so we can help publicise them.
  - Final reports should not be the first time Health is informed about delays or issues with project implementation. If the project is not going to meet significant milestones and deliverables by the research activity end date, submit a defer in-progress (for delays) or extend end date (for issues) variation request well before the activity end date.



### Grants management developments

• Financial reporting



- $\odot$  For NHMRC-administered grants:
  - project reporting and financial reporting timing are being aligned to eliminate requests for duplicate information
  - financial information will be removed from progress report templates in 2024
  - financial reports will now cover the financial year (July to June)
  - contact NHMRC MRFF Postaward if you are having issues with the change to the financial year financial reports.
- Streamlining the variation process



 for BGH-administered grants, we will shortly release forms to guide content development and procedures to support proactive, complete and timely submission of variation requests.




### Grants management developments

• RAO Seminars



- The Grants Management Office is holding in-person sessions in the Department's state offices over the next year.
- Eligible organisation staff supporting grants management, including research administration officers and finance officers, are welcome to attend.
- The sessions will offer a group seminar and an individual meeting with each grantee organisation to respond to specific questions about MRFF grants held.
- The sessions will focus on grants management (post-award) topics. Depending on staff availability, pre-award topics may be covered in some group seminars.
- MRFF grants management resources website



#### Gender Report Funding Rates Other reports

#### Assoc. Prof. Cindy Thamrin Director, Performance and Evaluation





#### **MRFF** reporting activities

The Department is working on improving its reporting of grants data to the public

- List of grants currently available at <u>https://www.health.gov.au/summary-of-mrff-grant-recipients</u>
- Report on financial support for medical research and innovation (latest May 2023, updated every two years) – *includes funded rates* <u>https://www.health.gov.au/resources/publications/financial-assistance-to-support-the-australian-medical-research-andinnovation-priorities-2020-2022</u>
- Gender data report (Aug 2023, updated annually) <u>https://www.health.gov.au/resources/publications/medical-research-future-fund-report-on-gender-data-for-grant-opportunities-august-2023</u>
- Themed reports on priority topics
  - Coronavirus research response (Mar 2023) <u>https://www.health.gov.au/resources/publications/medical-research-future-fund-report-on-the-coronavirus-research-response</u>
  - Rural, regional and remote health research (Aug 2023) <u>https://www.health.gov.au/resources/publications/medical-research-future-fund-report-on-funding-for-rural-regional-and-remote-health-research</u>



### Increasing MRFF data available


#### **MRFF Financial Assistance Report (May 2023)**

- MRFF financial assistance consistency with 2020–2022 priorities ۲
- **Funded** rates
- MRFF policies, performance and assurance activities •
- MRFF highlights and research snapshots...and more

#### MRFF Report on Funding for Rural, Regional and Remote Health Research (Aug 2023)

MRFF investment into RRR focused projects has increased since inception

- A rural focus has been embedded in a ٠ number of grant opportunities (through streams and eligibility criteria)
- Increased funds have been awarded to projects that are undertaken in rural areas, and to projects that address health topics of significance to rural areas of Australia



- a The total for 2019 includes the 2019 Rural, Regional and Remote Clinical Trial Enabling Infrastructure grant opportunity (\$124.4 million awarded).
- b The dataset for 2022 is not yet complete and does not include data for grant opportunities that opened in 2022 and for which outcomes are not yet available or have not been announced.
- c The number of projects funded includes grants with payments that commenced before or on 30 December 2022.

#### **MRFF** Coronavirus Research **Response Report (Mar 2023)**

\$1.30 million total funding



**80** projects funded

across all 4 broad research areas and 20 fields of research

with similar funded rates between males and females

#### Leading to:



the first Australian-made COVID-19 mRNA vaccine

the world's first 'living guidelines'



new ways to vaccinate against, diagnose and treat COVID-19

new ways to perform clinical trials



#### Some excerpts from the Financial Assistance Report (FAR)

#### The MRFF makes significant investments across all broad research areas

Broad research area	Number of grant opportunities completed	Funded grants	Funding	% of Funding
Basic Science	18	40	\$64,716,158.04	13.3%
Clinical Medicine and Science	23	136	\$277,096,247.86	56.8%
Health Services Research	18	64	\$92,819,599.82	19.0%
Public Health	17	35	\$53,516,135.56	11.0%

#### MRFF funded rates are above 30% (on average)


Broad research area	Number of applications	Funded grants	Funded rate
Basic Science	124	40	32.2%
Clinical Medicine and Science	424	136	32.1%
Health Services Research	179	64	35.8%
Public Health	95	35	36.8%

#### MRFF funded rates for women and men researchers are comparable

	Gender	Number of CIs in applications	Number of CIs in funded grants	Funded rate
All Chief Investigators (CIs)	Women	4415	1517	34.4%
	Men	5116	1591	31.1%
Lead Investigator (CIA)	Women	457	143	31.3%
	Men	564	156	27.7%

Data range: The report presents the financial assistance provided from the MRFF Special Account for the period when the *Australian Medical Research and Innovation Priorities 2020–2022* (2020–2022 Priorities) were in force; from 7 November 2020 to 5 November 2022.

#### Scientific articles of research supported by MRFF have higher impact than the global average





#### Some excerpts from the Financial Assistance Report (FAR)


#### Appendix G Funded rates of MRFF grant opportunities opened between 7 November 2020 and 5 November 2022

#### Table G Funded rates of MRFF grant opportunities

MRFF initiative	Grant opportunity	Applications	Applications funded	Funded rate	
Australian Brain Cancer Mission	2021 Brain Cancer Research	14	3	21.4%	
	2021 GBM AGILE	This grant opportunity was withdrawn.			
	2022 Australian Brain Cancer Research Infrastructure	2	1	50%	
	2020 Cardiovascular Health	75	16	21.3%	
Cardiovascular Health Mission	2021 Cardiovascular Health	100	41	41.0%	
	2022 Cardiovascular Health	51	14	27.5%	
	2021 Clinical Trials Activity	105	31	29.5%	
	2021 Innovative Therapies for Mental Illness	16	7	43.8%	
	2021 International Clinical Trial Collaborations (Round 21.1)	24	4	16.7%	
Clinical Trials Activity	2021 International Clinical Trial Collaborations (Round 21.2)	24	3	12.5%	
	2021 Rare Cancers, Rare Diseases and Unmet Need	97	29	29.9%	
	2022 International Clinical Trial Collaborations (Round 22.1)	20	3	15%	
	2022 International Clinical Trial Collaborations (Round 22.2)	No outcome available at the time this report was written.			
Clinical Trials Activity and Emerging Priorities and	2022 Multiple Sclerosis Research	No outcome available at the time this report was written.			
Consumer-Driven Research	2022 Pancreatic Cancer Research	9	4	44.4%	
Clinician Researchers	2020 Clinician Researchers: Applied Research in Health	181	14	7.7%	
	2022 Clinician Researchers: Nurses, Midwives and Allied Health	124	15	12.1%	



#### Some excerpts from the Gender Report



From inception up to 2021-22, averaged MRFF funded rates for women and men researchers are comparable

- 25.7% for both when considering all Chief Investigators
- 20.3% and 21.4% when considering leading Chief Investigators

2021–22 was the first financial year where more women than men applied for funding, for both leading and all Chief Investigators

Over the years, funded rates have increased progressively for women leading Chief Investigators

Gender balance is more equal when considering all Chief Investigators


Data range: The analysis for the current report was based on the subset of data from competitive grant opportunities that opened before 30 June 2022 and had outcomes data available as of 30 May 2023, and for which Chief Investigator data were available. The low number of applications from non-binary Chief Investigators were excluded from analysis for the current report was based on the subset of data from competitive grant opportunities that opened before 30 June 2022 and had outcomes data available as of 30 May 2023, and for which Chief Investigator data were available. The low number of applications from non-binary Chief Investigators were excluded from analysis for the current manalysis for the cureent manalysis for the current manal

Medical Research

#### Some excerpts from the Gender Report (contd.)

More women leading Chief Investigators applied for funding at a younger age and at an earlier career stage than men...


... but funded rates for women tended to be higher at later career stages



Data range: The analysis for the current report was based on the subset of data from competitive grant opportunities that opened before 30 June 2022 and had outcomes data available as of 30 May 2023, and for which Chief Investigator data were available. The low number of applications from non-binary Chief Investigators were excluded from analysis for the current report was based on the subset of data from competitive grant opportunities that opened before 30 June 2022 and had outcomes data available as of 30 May 2023, and for which Chief Investigator data were available. The low number of applications from non-binary Chief Investigators were excluded from analysis for the current report was based on the subset of data from competitive grant opportunities that opened before 30 June 2022 and had outcomes data available.







Consultation: Improving alignment and coordination between the MRFF and Medical Research Endowment Account (NHMRC)



- Diverse (and passionate) views from a broad range of research stakeholders
  - Researchers (universities, MRIs), health providers and services, businesses, consumers, priority populations - First Nations, rural/ regional/ remote, rare diseases
- Value of having both investigator-led and priority-driven approaches are well recognised
- Reform should promote and build on what works well in both funds
- End users of research (especially consumers) want to be involved and have an active role





#### Q&A





#### **Keep Connected**







## Thank you for your time